Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...

Tikka released the RoughTech Superlite model at nearly a pound lighter at 5.88 lbs versus the 6.6 lbs. of the standard T3x ...

TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR) ...

Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...

Our tested pick for the best overall MagSafe battery pack is the newly refreshed Baseus PicoGo Magnetic power bank thanks to its practical design and refined functionality. Read on to learn more ...

TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

The approval also helps shield from erosion of sales when Trikafta loses its patent, said William Blair analyst Myles Minter ahead of the decision. Cystic fibrosis is an inherited disease in which ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved a once-daily oral combination of ...